GET DAILY SIGNALSMDxHealth (MDXH) Reports Flat Q3 Revenue as Sales Organization Rebuilds
Key Takeaways
- Third quarter 2026 revenue from continuing operations was $22.7 million, essentially flat versus the prior-year period.
- Operating loss widened to $8.1 million from $4.4 million a year earlier, while net loss per share came in at $0.19.
- Management suspended its full-year 2026 revenue guidance of $110–115 million, citing unexpected sales-force turnover.
- Tissue-based test volume (Confirm mdx and GPS mdx) fell 11% to 11,232 tests, offset by stronger liquid-based Exo mdx volume of 11,792 tests.
- The company eliminated the Chief Commercial Officer (CCO) role and is rebuilding its sales organization ahead of 2027.
- Cash and cash equivalents stood at approximately $31.7 million at quarter-end, keeping liquidity in focus.
- For more details on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover automated strategies and market ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
MDxHealth is a urology-focused precision diagnostics company whose portfolio includes tissue-based Confirm mdx and GPS mdx tests and the liquid-based Exo mdx test. After delivering 16% revenue growth in the second quarter, the company entered the third quarter expecting to build on that momentum. Instead, the discontinuation of its Resolve mdx product line triggered unexpected attrition within its sales force, disrupting commercial execution and prompting management to suspend full-year guidance. For investors, this report matters because it tests whether MDxHealth can stabilize its commercial organization, protect its customer relationships, and return to the growth trajectory that had underpinned its turnaround narrative while managing a limited cash position. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, MDxHealth reported revenue from continuing operations of $22.7 million, essentially unchanged from $22.7 million a year earlier. Tissue-based test volume declined 11% to 11,232, while liquid-based Exo mdx volume rose to 11,792 from 4,600 in the prior-year period, reflecting the September 2025 acquisition.
Gross profit fell 5% to $14.0 million, with gross margin narrowing to 61.8% from 65%, largely due to a shift in test mix toward liquid-based volume. Operating expenses rose 16% to $22.2 million, driving an operating loss of $8.1 million compared with $4.4 million a year ago. Net loss per share was $0.19, wider than the roughly $0.07 per-share loss analysts had expected.
Adjusted EBITDA was negative $6.3 million. The company also confirmed it had suspended its full-year 2026 revenue guidance of $110–115 million and reported cash and cash equivalents of approximately $31.7 million at period-end. From what I see, the margin pressure from the test mix shift is a key detail worth monitoring.
Market Reaction and Investor Sentiment
Market sentiment around MDxHealth deteriorated well before the full report, as the company's October 15 preliminary revenue announcement already signaled the shortfall and the suspension of guidance. Shares have traded under pressure, reflecting a bearish technical trend and concerns about commercial execution, margin compression, and a shrinking cash position. The results underscored that the revenue miss was not a one-time event but the product of operational disruption, which has weighed on investor confidence. The restructuring—including the removal of the CCO role and a rebuilding of the sales force—was framed by management as a corrective step, but investors remain focused on whether the changes can restore growth quickly enough to support the company's liquidity and Nasdaq listing requirements.
Forward Outlook and Key Factors to Monitor
The most important near-term variable is the pace of the commercial rebuild. Management said it expects to exit the fourth quarter with a fully staffed sales organization positioned to return to growth in 2027, but hiring, onboarding, and ramping new sales representatives takes time and can extend the revenue disruption. I’m watching this closely because execution here will determine the near-term trajectory.
Investors should also watch liquidity. With roughly $31.7 million in cash and cash equivalents at quarter-end and ongoing operating losses, the company's cash runway and any need for additional financing will remain central to the story.
On the clinical front, the company continues to emphasize its GPS mdx test, supported by academic validation efforts such as the Oxford ProMPT study and the planned GPS-ProtecT randomized controlled trial. Positive data or guideline updates could reinforce long-term demand, but they are unlikely to offset near-term commercial headwinds.
Finally, MDxHealth has received Nasdaq notices related to minimum bid price and market value requirements, so regaining compliance is another factor investors will monitor alongside margin trends and the reimbursement environment for its diagnostic tests.
Using Tickeron’s AI Tools in My Analysis
In my day-to-day research, Tickeron’s AI Screener serves as a practical way to scan healthcare and diagnostics names for technical patterns, fundamentals, and performance metrics. It helps surface comparable opportunities and monitor shifting conditions without spending hours on manual work. I find it particularly useful when evaluating how names like MDxHealth stack up against peers during periods of operational change.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXH's RSI Indicator stays in oversold zone for 18 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MDXH just turned positive on November 06, 2026. Looking at past instances where MDXH's MACD turned positive, the stock continued to rise in 24 of 30 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 96 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 37 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MDXH entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (67.298). P/E Ratio (0.000) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement